Piper Sandler analyst Biren Amin maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...

In an exciting advancement for dermatological science, researchers have uncovered the pivotal role of vitamin D and the ...

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel ...

R Squared Ltd purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the 4th quarter, according to its ...

In a new study, Yale researchers have started to uncover what happens at the cellular and molecular levels as skin fibrosis progresses, and the findings, they say, yield potential targets for treating ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $9.26, as investors respond to a series of market headwinds. According to InvestingPro data, the stock's ...

UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Constrictive bronchiolitis obliterans is an important respiratory illness because of its underlying irreversible fibrotic process, and is defined as concentric fibrosis in the bronchiolar ...

FY25 saw AdAlta focus on increasing its corporate muscle, with two new board members and additional advisors engaged. ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...